Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770733 | 0.91 | PDE10A (0.32) | PDE10ASCN10AHCRTR1HCRTR2SCN1A | |
| SCHEMBL23770496 | 0.80 | RAF1 (0.35) | — | |
| SCHEMBL19925210 | 0.79 | ROS1 (0.36) | PDE10ASCN10AHCRTR1HCRTR2SCN1A | |
| SCHEMBL23770833 | 0.78 | ADRB2 (0.39) | ALK | |
| SCHEMBL23770477 | 0.76 | MAPK10 (0.36) | SCN10AHCRTR1HCRTR2SCN1ASCN5A | |
| SCHEMBL23770441 | 0.71 | HTR3E (0.43) | SCN9A | |
| SCHEMBL23770749 | 0.71 | MPL (0.33) | PDE10AHCRTR1HCRTR2 | |
| SCHEMBL23770744 | 0.70 | RAF1 (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL23770830 | 0.70 | MAP4K1 (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL23770818 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |